These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 24956412)

  • 21. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.
    Piert M; Montgomery J; Kunju LP; Siddiqui J; Rogers V; Rajendiran T; Johnson TD; Shao X; Davenport MS
    J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
    Pokorny MR; de Rooij M; Duncan E; Schröder FH; Parkinson R; Barentsz JO; Thompson LC
    Eur Urol; 2014 Jul; 66(1):22-9. PubMed ID: 24666839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy].
    Kesch C; Radtke JP; Distler F; Boxler S; Klein T; Hüttenbrink C; Hees K; Roth W; Roethke M; Schlemmer HP; Hohenfellner M; Hadaschik BA
    Urologe A; 2016 Aug; 55(8):1071-7. PubMed ID: 27168038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy.
    Muller BG; Kaushal A; Sankineni S; Lita E; Hoang AN; George AK; Rais-Bahrami S; Kruecker J; Yan P; Xu S; de la Rosette JJ; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    Urol Oncol; 2015 Oct; 33(10):425.e1-425.e6. PubMed ID: 26259666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeat Targeted Prostate Biopsy under Guidance of Multiparametric MRI-Correlated Real-Time Contrast-Enhanced Ultrasound for Patients with Previous Negative Biopsy and Elevated Prostate-Specific Antigen: A Prospective Study.
    Jang DR; Jung DC; Oh YT; Noh S; Han K; Kim K; Rha KH; Choi YD; Hong SJ
    PLoS One; 2015; 10(6):e0130671. PubMed ID: 26083348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiparametric 3T MRI in the evaluation of intraglandular prostate cancer: correlation with histopathology.
    Styles C; Ferris N; Mitchell C; Murphy D; Frydenberg M; Mills J; Pedersen J; Bergen N; Duchesne G
    J Med Imaging Radiat Oncol; 2014 Aug; 58(4):439-48. PubMed ID: 24935089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
    Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
    Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnetic resonance imaging targeted biopsy in men with previously negative prostate biopsy results.
    Lee SH; Chung MS; Kim JH; Oh YT; Rha KH; Chung BH
    J Endourol; 2012 Jul; 26(7):787-91. PubMed ID: 22122555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.
    Fütterer JJ; Briganti A; De Visschere P; Emberton M; Giannarini G; Kirkham A; Taneja SS; Thoeny H; Villeirs G; Villers A
    Eur Urol; 2015 Dec; 68(6):1045-53. PubMed ID: 25656808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Value of MRI/ultrasound fusion in primary biopsy for the diagnosis of prostate cancer].
    Distler F; Radtke JP; Kesch C; Roethke M; Schlemmer HP; Roth W; Hohenfellner M; Hadaschik B
    Urologe A; 2016 Feb; 55(2):146-55. PubMed ID: 26556268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging.
    Tamada T; Sone T; Higashi H; Jo Y; Yamamoto A; Kanki A; Ito K
    AJR Am J Roentgenol; 2011 Sep; 197(3):664-70. PubMed ID: 21862809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner.
    Singh AK; Krieger A; Lattouf JB; Guion P; Grubb RL; Albert PS; Metzger G; Ullman K; Smith S; Fichtinger G; Ocak I; Choyke P; Ménard C; Coleman J
    BJU Int; 2008 Jan; 101(2):181-5. PubMed ID: 17922874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of quantitative diffusion-weighted and dynamic contrast-enhanced MRI parameters with prognostic factors in prostate cancer.
    Chung MP; Margolis D; Mesko S; Wang J; Kupelian P; Kamrava M
    J Med Imaging Radiat Oncol; 2014 Oct; 58(5):588-94. PubMed ID: 25196228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer.
    Otti VC; Miller C; Powell RJ; Thomas RM; McGrath JS
    BJU Int; 2019 Jan; 123(1):82-90. PubMed ID: 29804315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL.
    Lee DH; Nam JK; Park SW; Lee SS; Han JY; Lee SD; Lee JW; Chung MK
    Yonsei Med J; 2016 May; 57(3):565-71. PubMed ID: 26996553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A role of multifactorial evaluation of prostatic 3T MRI in patients with elevated prostatic-specific antigen levels: prospective comparison with ultrasound-guided transrectal biopsy.
    Ferda J; Kastner J; Hora M; Hes O; Fínek J; Topolčan O; Kreuzberg B
    Anticancer Res; 2013 Jun; 33(6):2791-5. PubMed ID: 23749943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4-10 ng/mL.
    Dwivedi DK; Kumar R; Dwivedi AK; Bora GS; Thulkar S; Sharma S; Gupta SD; Jagannathan NR
    J Magn Reson Imaging; 2018 May; 47(5):1227-1236. PubMed ID: 28872226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen.
    Quentin M; Blondin D; Arsov C; Schimmöller L; Hiester A; Godehardt E; Albers P; Antoch G; Rabenalt R
    J Urol; 2014 Nov; 192(5):1374-9. PubMed ID: 24866597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level--can it rule out clinically significant prostate cancer?
    Abd-Alazeez M; Ahmed HU; Arya M; Charman SC; Anastasiadis E; Freeman A; Emberton M; Kirkham A
    Urol Oncol; 2014 Jan; 32(1):45.e17-22. PubMed ID: 24055430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the prostate imaging reporting and data system for the detection of prostate cancer by the results of targeted biopsy of the prostate.
    Baur AD; Maxeiner A; Franiel T; Kilic E; Huppertz A; Schwenke C; Hamm B; Durmus T
    Invest Radiol; 2014 Jun; 49(6):411-20. PubMed ID: 24598440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.